Wordt geladen...
Chronic myelogenous leukemia on target
Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro‐leukemic activity of the BCR‐ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off‐target effects, treatment‐induced drug resistance, and the limited effect of the...
Bewaard in:
| Gepubliceerd in: | Cancer Med |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6051163/ https://ncbi.nlm.nih.gov/pubmed/29905026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1604 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|